Apolipoprotein B (ApoB) is a direct measure of the total number of atherogenic lipoprotein particles in your blood — each LDL, VLDL, and IDL particle carries exactly one ApoB molecule. This makes ApoB a more accurate predictor of cardiovascular risk than LDL-C alone. But when a result comes back from the lab, what does "normal" actually mean?
The answer depends on which definition of normal you're using — and for cardiovascular prevention, the two definitions point to very different numbers.
ApoB "Normal" vs. Cardiovascular Target
Lab reference ranges (population-based): 66–133 mg/dL (males) · 60–117 mg/dL (females)
Cardiovascular prevention targets: <90 mg/dL (most adults) · <80 mg/dL (high risk) · <65 mg/dL (very high risk)
A result inside the lab reference range does not mean your ApoB is at a safe level for cardiovascular prevention.
Standard Laboratory Reference Ranges
Most clinical laboratories report ApoB within the following general population reference ranges:
| Sex | Lab Reference Range | Source |
|---|---|---|
| Males | 66–133 mg/dL | Cleveland Clinic Laboratory |
| Females | 60–117 mg/dL | Cleveland Clinic Laboratory |
Important caveat: These reference ranges are derived from the statistical distribution of the general population — not from the levels associated with optimal cardiovascular health. In a population where subclinical atherosclerosis is common, a "normal" lab range can still reflect meaningful cardiovascular risk.
Cardiovascular Risk Targets: What the Guidelines Say
For cardiovascular prevention, ApoB targets are risk-stratified — meaning the appropriate target depends on your overall risk category, not on a single universal cutoff. This is the clinically meaningful way to interpret an ApoB result.
ApoB Target Ranges by Risk Category
| Risk Category | ApoB Target | Who This Applies To |
|---|---|---|
| Low / Moderate | <90 mg/dL | Most adults without established cardiovascular disease or major risk factors |
| High Risk | <80 mg/dL | Diabetes · CKD · Multiple major risk factors · Markedly elevated individual risk factors |
| Very High Risk | <65 mg/dL | Prior MI/stroke · Established ASCVD · Familial hypercholesterolaemia · Severe CKD |
| Longevity / Primary Prevention | <55 mg/dL | Some longevity-focused frameworks for younger, low-risk individuals — not yet universally adopted in major guidelines |
The <90, <80, and <65 mg/dL targets are referenced in the 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias and are increasingly reflected in ACC/AHA guidance as well. The 2026 AHA/ACC guidelines now formally include ApoB targets alongside LDL-C for cardiovascular risk assessment.
Why "Lower Is Better" for ApoB
ApoB has a linear, causal relationship with atherosclerosis. Unlike some other biomarkers, there is no established lower threshold below which ApoB is considered harmful in an otherwise healthy person. The relationship between ApoB reduction and cardiovascular event reduction is consistent across the evidence base — making lower ApoB a straightforward goal for cardiovascular prevention.
Mendelian randomization studies — which use genetic variation to isolate causal relationships — have consistently identified ApoB as the primary lipid determinant of coronary artery disease, ahead of LDL-C, triglycerides, and other lipid markers. This causal evidence underpins the guideline movement toward ApoB-inclusive risk assessment.
Lower is better
ApoB has a linear causal relationship with atherosclerosis. Every unit reduction in ApoB translates to reduced cardiovascular risk — with no established lower safety limit.
Discordance is common
Approximately 15–20% of people have elevated ApoB with "normal" LDL-C — meaning standard lipid panels miss meaningful risk in roughly 1 in 5 people.
Targets are risk-stratified
The same ApoB value can be acceptable for a low-risk individual and significantly above target for someone with established cardiovascular disease.
Not on standard panels
ApoB is not included in a routine lipid panel. It must be ordered separately — which is why most people have never had it measured.
When ApoB Is Most Likely to Reveal Hidden Risk
The gap between LDL-C and ApoB is largest in specific clinical contexts — exactly the populations where ApoB testing adds the most value:
In people with insulin resistance, metabolic syndrome, or elevated triglycerides, the liver tends to produce many small, cholesterol-depleted LDL particles. Each carries less cholesterol than average — keeping LDL-C lower — while ApoB accurately counts the total particle burden. This is where LDL-C most consistently understates cardiovascular risk.
When to Test ApoB
ApoB Testing Is Recommended When:
LDL-C and clinical risk don't align — when LDL-C looks acceptable but overall risk profile suggests otherwise (elevated triglycerides, low HDL, central obesity)
Family history of premature cardiovascular disease — first-degree relative with MI or stroke before age 55 (men) or 65 (women)
Metabolic syndrome, diabetes, or CKD — conditions strongly associated with the small dense LDL phenotype driving ApoB-LDL discordance
Considering therapy intensification — when LDL-C appears "on-target" but residual cardiovascular risk remains unexplained
Monitoring treatment response — ApoB is the more appropriate metric when ApoB-LDL discordance has been documented, since LDL-C alone may miss residual particle burden
Common Questions
Not necessarily. Laboratory reference ranges (up to 133 mg/dL for males) are derived from the general population — not from cardiovascular safety thresholds. A result of 95 mg/dL might be labelled "normal" on a standard lab report while still being above the <90 mg/dL target for primary prevention and well above the <65 mg/dL target for very-high-risk individuals. Always interpret ApoB in the context of your overall risk profile.
LDL-C measures the mass of cholesterol carried inside LDL particles — it is a measure of cargo weight. ApoB counts the total number of atherogenic particles (LDL, VLDL, IDL, Lp(a)) — it is a measure of vehicle count. Two people with identical LDL-C can have very different ApoB levels if their particle sizes differ. See the full comparison in ApoB: The Complete Guide.
Some longevity-focused frameworks suggest <55 mg/dL as an optimal target for primary prevention in younger, lower-risk individuals — based on the evidence that ApoB reduction correlates linearly with reduced atherosclerotic burden. However, this is not yet a universally adopted guideline recommendation. The major international guideline bodies (ESC/EAS, ACC/AHA) set <65 mg/dL as the target for very-high-risk patients, with <90 mg/dL as desirable for most adults.
For patients whose elevated ApoB is primarily metabolically driven — by insulin resistance, visceral adiposity, or a diet high in refined carbohydrates — meaningful reductions through dietary change, weight management, and aerobic exercise are well-supported by evidence. For patients with genetic dyslipidemias such as familial hypercholesterolaemia, lifestyle alone is generally insufficient and pharmacotherapy is required.
Lp(a) particles carry their own ApoB molecule, so Lp(a) is counted within your total ApoB measurement. However, an elevated ApoB cannot tell you how much of it is driven by Lp(a) specifically — that requires a separate Lp(a) test. See Lp(a) vs LDL: Why a Normal Cholesterol Test Can Miss a Serious Risk Factor for more detail.
Know Where Your ApoB Stands
CardioIQ interprets your ApoB result in the context of your full lipid panel, your risk category, and current ESC/EAS and ACC/AHA guideline targets — telling you exactly where you stand and what it means.
Important Medical Notice. This article is for educational and informational purposes only. Reference ranges and targets cited reflect published guideline recommendations and may differ from your laboratory's reference range. Always consult a qualified physician before making decisions about your health or treatment.
References
- 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal. doi:10.1093/eurheartj/ehz455
- 2018 AHA/ACC/Multisociety Guideline on the Management of Blood Cholesterol. JACC. doi:10.1016/j.jacc.2018.11.003
- Cleveland Clinic. Apolipoprotein B (ApoB) Test. my.clevelandclinic.org
- ApoB, LDL-C and non-HDL-C as markers of cardiovascular risk: systematic review (n≈600,000). Journal of Clinical Lipidology, 2025. PubMed: 40681368
- Zuber V et al. High-throughput multivariable Mendelian randomization prioritises ApoB as key lipid risk factor for coronary artery disease. International Journal of Epidemiology, 2021. doi:10.1093/ije/dyab074
- Mayo Clinic Laboratories. Apolipoprotein B Test. mayocliniclabs.com
- WebMD. What Is the Apolipoprotein B Test? webmd.com